investing money


Oil futures rose for a fourth straight session on Wednesday, trading at nearly 18-month highs on expectations the Organization of the Petroleum Exporting Countries and other major producing nations will make good on promises to cut output in the new year.

On the New York Mercantile Exchange, light, sweet crude futures for delivery in February CLG7, -0.55% gained 16 cents a barrel, or 0.3%, to finish at $54.06their highest close since July 2, 2015.

investing money: Amira Nature Foods Ltd(ANFI)


Advisors’ Opinion:

  • [By Roberto Pedone]

    Another earnings short-squeeze prospect is packaged specialty rice and other food products distributor Amira Nature Foods (ANFI), which is set to release numbers on next Monday after the market close. Wall Street analysts, on average, expect Amira Nature Foods to report revenue of $132.37 million on earnings of 32 cents per share.

    The current short interest as a percentage of the float for Amira Nature Foods is extremely high at 26.6%. That means that out of 17.70 million shares in the tradable float, 4.72 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 8.2%, or by 356,000 shares. If the bears get caught pressing their bets into a bullish quarter, then shares of ANFI could easily rip sharply higher post-earnings as the shorts move fast to cover some of their trades.


    From a technical perspective, ANFI is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock just recently bounced higher off some near-term support at $15.25 a share. That bounce is starting to push shares of ANFI within range of triggering a near-term breakout trade post-earnings.

    If you’re bullish on ANFI, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $17 to $17.98 a share and then above more resistance at $18.52 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 174,102 shares. If that breakout develops post-earnings, then ANFI will set up to re-test or possibly take out its next major overhead resistance levels at $19.86 to $20.29 a share, or even its 52-week high at $25 a share.


    I would simply avoid ANFI or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below some key near-term supp

investing money: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

investing money: Prudential Financial Inc.(PRU)

Advisors’ Opinion:

  • [By Chuck Saletta]

    Prudential Financial (NYSE:PRU) has long had the Rock of Gibraltar as its corporate symbol, representing its solid financial position. With more cash and equivalents than debt on its balance sheet, and a total cash hoard of over $49 billion, Prudential still looks set up to handle some downright awful insurable losses. That’s its “Rock of Gibraltar” strength showing through.

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

    Read more of Cramer’s comments about the stocks in the Lightning Round.

  • [By WWW.MONEYSHOW.COM]

    Prudential Financial (PRU) is also a major provider of asset management and retirement services. It focuses is on fixed income, a major liability during the past eight years of ultra-low interest rates.

investing money: Masimo Corporation(MASI)


Advisors’ Opinion:

  • [By Keith Speights, Sean Williams, and Cory Renauer]

    So when we asked three of our top healthcare contributors to name three of the best stocks to invest in healthcare, it’s not surprising that their responses listed companies in three different industries: medical device makerMasimo (NASDAQ:MASI), pharmacy services giant CVS Health (NYSE:CVS) and biopharmaceutical company Ligand Pharmaceuticals (NASDAQ:LGND). Here’s why these three healthcare stocks stand out as smart picks.

investing money: Alder BioPharmaceuticals, Inc.(ALDR)

Advisors’ Opinion:

  • [By Paul Ausick]

    Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) posted a new 52-week low of $13.50on Tuesday, down nearly 28% compared with Monday’s closing price of $18.70. The stock’s 52-week high is $36.48. Volume totaled more than 12 million shares, about 12 times the daily average of around 720,000. The company reported that its migraine treatment reported a positive result, but investors were not impressed.

Leave a Reply

Your email address will not be published. Required fields are marked *